Yan Zhang, PhD, Jeanne Stuckey, PhD, Markus Ruetz, PhD, Michael Cianfrocco, PhD, and Wei Cheng, PhD, have been promoted.

The newest version of the heparin reversal drug, described in a recent issue of Advanced Healthcare Materials, adjusted the number of protons bound to it, making the molecule less positive so it would preferentially bind to the highly negative heparin, resulting in a much safer drug.

A melanoma survivor shares facts and tips about preventing all types of skin cancer.

Recent research achievements from the Giessen lab.

Recent developments represent a dramatic change from long standing federal policy around these substances that has historically criminalized their use and blocked or delayed research efforts into their therapeutic potential.

A research team, led by Michigan Medicine and in partnership with Hurley Medical Center, finds that nearly three-quarters of patients at a clinic in Flint, Mich., a community that is predominantly Black and socioeconomically disadvantaged, had neuropathy — of which 75% was undiagnosed.

Today on The Fundamentals, our guest Dr. Martin Myers, Director of the U-M Elizabeth Weiser Caswell Diabetes Institute, discusses diabetes research in the context of Ozempic, Wegovy, and other drugs that are changing how people think about weight loss. You can learn more about Dr. Myers here, and you can follow the department of molecular and integrative physiology @UMPhysiology on X.

People over 50 of all backgrounds say they’re most concerned about various kinds of health costs affecting people their age, including insurance, prescriptions, medical care, dental care and home or longterm care.

Building a comprehensive human kidney cell and tissue catalog could help develop more treatments for kidney disease.

Researchers have used advanced computer algorithms to uncover distinct molecular subgroups of kidney diseases, independent of clinical classifications. These findings have significant implications for personalized treatment approaches.

A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

Researchers recently revealed a new mechanism behind antiphospholipid syndrome that the investigators hope will eventually allow treatments to be targeted closer to the source of the problem.

The FDA approved the use of a therapeutic device invented and developed at the University of Michigan for use in children with acute kidney injury and sepsis or a septic condition requiring continuous kidney replacement therapy.